Isis Pharmaceuticals, Inc. Form 10K - page 1

FORWARD-LOOKINGSTATEMENTS
This report on Form10-K and the information incorporated herein by reference includes
forward-looking statements regarding our business, the therapeutic and commercial potential of our
technologies and drugs, including KYNAMRO, ISIS-APOCIIIRx, ISIS-SMNRx and ISIS-TTRRx, and other
products in development, and the financial position of Isis Pharmaceuticals, Inc. Any statement describing
our goals, expectations, financial or other projections, intentions or beliefs, is a forward-looking statement
and should be considered an at-risk statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business
around such drugs. Our forward-looking statements also involve assumptions that, if they never
materialize or prove correct, could cause our results to differmaterially from those expressed or implied
by such forward-looking statements. Factors that could cause or contribute to such differences include, but
are not limited to, those discussed in this report on Form10-K, including those identified in Item1A
entitled ‘‘Risk Factors’’. Although our forward-looking statements reflect the good faith judgment of our
management, these statements are based only on facts and factors currently known by us. As a result, you
are cautioned not to rely on these forward-looking statements.
In this report, unless the context requires otherwise, ‘‘Isis,’’ ‘‘Company,’’ ‘‘we,’’ ‘‘our,’’ and ‘‘us’’ refers to Isis
Pharmaceuticals, Inc. and its subsidiaries.
TRADEMARKS
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.
Akcea Therapeutics™ is a trademark of Isis Pharmaceuticals, Inc.
Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.
KYNAMRO® is a registered trademark of Genzyme Corporation
KYNAMROCornerstoneSM is a service mark of Genzyme Corporation
Zytiga® is a registered trademark of Janssen Biotech, Inc.
ABRAXANE® is a registered trademark of Celgene Corporation
Vyndaqel® is a registered trademark of Pfizer Inc.
Glybera® is a registered trademark of uniQure NV
CORPORATE INFORMATION
We incorporated in California in 1989, and in January 1991 we changed our state of incorporation to
Delaware. Our principal offices are in Carlsbad, California. We make available, free of charge, on our website,
www.isispharm.com, our reports on Forms 10-K, 10-Q, 8-K and amendments thereto, as soon as reasonably
practical after we file such materials with the Securities and Exchange Commission. Any information that we
include on or link to our website is not a part of this report or any registration statement that incorporates this
report by reference. You may also read and copy our filings at the SEC’s Public Reference Room at 100 F
Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room
by calling the SEC at 1-800-732-0330. The SEC also maintains a website that contains reports, proxy and
information statements, and other information regarding issuers that file electronically with the SEC. The address
of that site is www.sec.gov.
1